Exploring the best treatment combinations for advanced triple-negative breast cancer
A Prospective, Multicenter Clinical Trial Exploring the Optimal Combination Strategies of Radiotherapy and Immunotherapy for Advanced Triple-Negative Breast Cancer
PHASE2 · Sun Yat-sen University · NCT06735131
This study is testing different combinations of radiation and immune therapy to see if they can help people with advanced triple-negative breast cancer live longer and feel better.
Quick facts
| Phase | PHASE2 |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Sex | All |
| Sponsor | Sun Yat-sen University (other) |
| Drugs / interventions | chemotherapy, radiation, immunotherapy, Pembrolizumab, Atezolizumab, Toripalimab |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT06735131 on ClinicalTrials.gov |
What this trial studies
This study investigates optimal combinations of radiotherapy and immunotherapy for patients with advanced triple-negative breast cancer (TNBC). Given the aggressive nature of metastatic TNBC and the limitations of traditional chemotherapy, the trial aims to enhance treatment efficacy by integrating immune checkpoint inhibitors with various radiotherapy regimens. Participants will receive different radiotherapy doses and schedules alongside selected chemotherapy agents, with the goal of improving progression-free and overall survival rates. The study will also monitor for potential immune-related adverse events associated with the treatments.
Who should consider this trial
Good fit: Ideal candidates include individuals with inoperable locally advanced or metastatic TNBC who have not received prior chemotherapy for advanced disease.
Not a fit: Patients with operable tumors or those who have previously undergone chemotherapy for advanced/metastatic TNBC may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a more effective treatment strategy for patients with advanced TNBC, potentially improving survival outcomes.
How similar studies have performed: While there have been studies exploring immunotherapy in TNBC, the specific combination of radiotherapy and immunotherapy in this manner is relatively novel and untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria:
1. Inoperable locally advanced/metastatic triple-negative breast cancer (defined as ER and PR \<1%; and HER2 negative as IHC 0 or IHC 1+, or IHC 2+ but negative upon fluorescence in situ hybridization (FISH) testing). Patients with ER/PR ≤10% and deemed unsuitable for endocrine therapy by the investigator are also eligible.
2. No prior chemotherapy for advanced/metastatic disease.
3. ECOG PS score of 0 or 1.
4. Presence of 1 to 5 tumor lesions suitable for radiotherapy (individual lesion size between 0.5 and 5 cm, not limited to 1 to 2 organs).
5. At least one measurable lesion outside the radiation field that can be evaluated.
6. Suitable to receive one of the chemotherapy regimens chosen by the investigator: nab-paclitaxel or gemcitabine + carboplatin.
7. Patients with brain metastases are allowed if they do not require local therapy at enrollment or if the metastatic lesion is treated with the assigned radiotherapy regimen.
8. Patients who have previously received PD-1/PD-L1 therapy for early-stage disease are allowed to enroll.
9. Able to provide tumor tissue sections or agree to tumor biopsy during the screening period.
10. Adequate organ and bone marrow function, with specific requirements:
1. Hematology: Neutrophil count (ANC) ≥1.5×10\^9/L; Platelet count (PLT) ≥90×10\^9/L; Hemoglobin (Hb) ≥90 g/L; No blood product transfusion (including red blood cell and platelet products, etc.) or growth factor (including colony-stimulating factors, interleukins, and erythropoietin, etc.) support treatment within 2 weeks prior to examination.
2. Liver function: Serum total bilirubin (TBIL) ≤1.5×upper limit of normal (ULN); Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) ≤2.5×ULN (for patients with liver metastases: ALT and AST ≤5×ULN).
3. Renal function: Serum creatinine (Cr) ≤1.5×ULN or creatinine clearance \>60 mL/min.
Exclusion Criteria:
1. Received platinum-containing regimens during the adjuvant/neoadjuvant therapy phase, and the interval from the last treatment to recurrence/metastasis is less than 6 months.
2. Have received radiotherapy within 12 weeks prior to enrollment, unless the radiotherapy was for adjuvant purposes and there are lesions outside the previously irradiated field.
3. Extensive tumor metastasis with surrounding normal tissues that cannot tolerate radiotherapy damage.
4. Significant third-space fluid retention (e.g., ascites, pleural effusion, pericardial effusion).
5. Require long-term systemic corticosteroid treatment.
6. Have active autoimmune diseases.
7. Have concurrent severe infections.
8. Other patients deemed unsuitable for enrollment by the investigator.
Where this trial is running
Guangzhou, Guangdong
- Sun Yat-sen University Cancer Center — Guangzhou, Guangdong, China (RECRUITING)
Study contacts
- Study coordinator: Shusen Wang, MD
- Email: wangshs@sysucc.org.cn
- Phone: +86-02087342491
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Triple-Negative Breast Cancer, radiotherapy, immunotherapy, chemotherapy, triple-negative breast cancer